Primecap Management’s Decoy Therapeutics DCOY Stock Holding History

Primecap Management’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Hold	0	–	-$13K	–	294
2018 Q4	–	Hold	0	–	–	–	291
2018 Q3	–	Sell	-2	Closed	-$1.16M	–	292
2018 Q2	$1.7M	Hold	2	–	–	﹤0.01%	276
2018 Q1	$9.06M	Hold	2	–	–	0.01%	238
2017 Q4	$6.3M	Hold	2	–	–	﹤0.01%	245
2017 Q3	$5.73M	Hold	2	–	–	﹤0.01%	246
2017 Q2	$6.07M	Hold	2	–	–	0.01%	247
2017 Q1	$6.48M	Buy	2 +1	+100%	+$4.08M	0.01%	246
2016 Q4	$5.72M	Hold	1	–	–	0.01%	246
2016 Q3	$10.1M	Hold	1	–	–	0.01%	225
2016 Q2	$8.07M	Hold	1	–	–	0.01%	227
2016 Q1	$6.96M	Buy	+1	New	+$8.04M	0.01%	233
2015 Q4	–	Hold	0	–	–	–	235
2015 Q3	–	Hold	0	–	–	–	246
2015 Q2	–	Hold	0	–	–	–	233
2015 Q1	–	Hold	0	–	–	–	230

Other funds holding DCOY

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AIP

Ahrens Investment Partners Lafayette, Louisiana $202M AUM 3.91% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Primecap Management's DCOY Position: Q1 2019 in Review

Primecap Management held its Decoy Therapeutics (DCOY) position steady in Q1 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #294.

Primecap Management first reported a position in DCOY in Q1 2016 and has held it in 10 quarters since. The position peaked at $10.1M in Q3 2016. 1 fund tracked by Wall St. Rank holds DCOY as of Q1 2019.

Primecap Management held 0 shares of Decoy Therapeutics worth $0 as of Q1 2019.
Primecap Management left its Decoy Therapeutics share count unchanged in Q1 2019.
Decoy Therapeutics made up ﹤0.01% of Primecap Management's portfolio in Q1 2019, its #294 holding.
Primecap Management first reported a position in Decoy Therapeutics in Q1 2016 and has held it in 10 quarters since.
Primecap Management's Decoy Therapeutics position peaked at $10.1M in Q3 2016.
1 fund tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2019.

Based on Primecap Management's 13F filing for Q1 2019, filed 14 May 2019.